作者: A. J. Lurie , B. Djulbegovic , J. R. Nebeker , C. Angelotta , L. I. Gordon
DOI: 10.1200/JCO.2006.24.18_SUPPL.6026
关键词:
摘要: 6026 Background: Since 1992, the Food and Drug Administration (FDA) has allowed accelerated approval of novel cancer drugs based on improvements in surrogate outcomes, provided that subsequent phas...